The global gene delivery technologies market size is expected to reach USD 7.86 billion by 2028 according to a new study by Polaris Market research. The report “Gene Delivery Technologies Market Share, Size, Trends, Industry Analysis Report, By Mode (Biological [Adenovirus, Retrovirus, AAV, Lentivirus, Other Viruses, Non-viral], Chemical, Physical); By Application (Gene Therapy, Cell Therapy, Vaccines, Research); By Method; By Regions; Segment Forecast, 2021 –2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
In 2020, the gene therapy market segment accounted for the largest share. Worldwide acceptance of gene therapies and subsequent rise in clinical research activities have boosted the segment’s market growth. Moreover, rising approvals for gene therapy products and services also accelerated the gene delivery technologies market growth prospects.
The vaccine market segment is projected to witness a lucrative growth rate over the gene delivery technologies study period. This is primarily due to the ability of such vaccines for different treatment approaches for both preventive and therapeutic areas. They have the potential to activate potent humoral responses. This has boosted the demand for gene editing tools for vaccine development.
Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/gene-delivery-technologies-market/request-for-sample
Market participants in gene delivery technologies industry include Horizon Discovery Group Co., QIAGEN, Oxford Biomedica, SignaGen Laboratories, Hoffmann-La Roche AG, Vectalys, Sirion-Biotech GmbH, Takara Bio Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., OriGene Technologies, Inc., System Biosciences, Promega Corporation, and Catalent Inc.
The market players operating in the gene delivery technologies industry are focusing on mergers and acquisitions to stay competitive in the market. In line with this, in May 2020, Merck, completed the acquisition of Themis, an immune-modulation therapy to expand its vaccine development program for the surging COVID-19 numbers. Similarly, earlier, in May 2019, already acquired Brammer Bio, a U.S.-based company engaged in the development of viral vectors to be used in gene therapies.
Get Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/gene-delivery-technologies-market/request-for-discount-pricing
Polaris Market Research has segmented the gene delivery technologies market report on the basis of mode, application, method, and region:
Gene Delivery Technologies, Mode Outlook (Revenue – USD Million, 2016 – 2028)
- Biological
- Adenovirus
- Retrovirus
- AAV
- Lentivirus
- Other viruses
- Non-viral
- Chemical
- Physical
Gene Delivery Technologies, Application Outlook (Revenue – USD Million, 2016 – 2028)
- Gene Therapy
- Cell Therapy
- Vaccines
- Research
Gene Delivery Technologies, Method Outlook (Revenue – USD Million, 2016 – 2028)
- Ex vivo
- In vivo
- In vitro
Buy Now @ https://www.polarismarketresearch.com/checkouts/8241
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
Email: [email protected]
Web: www.polarismarketre